<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386122</url>
  </required_header>
  <id_info>
    <org_study_id>CCP2018-BE.07</org_study_id>
    <nct_id>NCT04386122</nct_id>
  </id_info>
  <brief_title>An in Vivo Bioequivalence Study of 2 Loxoprofen Sodium Products in Vietnamese Healthy Male Volunteers</brief_title>
  <official_title>An in Vivo Bioequivalence Study of FABALOFEN 60 (Loxoprofen Sodium 60mg/Tablet) of Pharbaco Central Pharmaceutical J.S.C No.I With JAPROLOX速 TABLETS (Loxoprofen Sodium 60mg/Tablet) of Daiichi Sankyo Propharma Co., Ltd</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre of Clinical Pharmacology, Hanoi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Clinical Pharmacology, Hanoi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate whether FABALOFEN 60 is bioequivalent to JAPROLOX速 TABLETS&#xD;
      after a single oral administration of each loxoprofen formulation in healthy subjects by&#xD;
      assessing of pharmacokinetic properties including AUC, Tmax and Cmax and to evaluate the&#xD;
      safety of test drug FABALOFEN 60 and reference drug JAPROLOX速 TABLETS during drug&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single-dose, 2-sequence, 2-period, 2-treatment crossover study in&#xD;
      24 fed healthy subjects with an at-least-6-day washout period. The drug level in serum is&#xD;
      detected by High-performance Liquid Chromatography (HPLC) to determine Cmax, AUC0-t and Tmax.&#xD;
      Safety are evaluated during drug administration, blood sampling time, washout period and 1&#xD;
      week after the end of blood sampling for any adverse drug reactions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized, single-dose, 2-sequence, 2-period, 2-treatment crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Up to 8 hours post-administration</time_frame>
    <description>Area under the plasma concentration curve from time 0 to the last measured (AUC0-t). Analyzing AUC with ANOVA test to evaluate the 90% confidence interval for the ratio (Test/Reference) of the population mean with a logarithmic transformation prior to analysis with acceptance interval of 0.80 - 1.25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 8 hours post-administration</time_frame>
    <description>Maximum plasma concentration. Analyzing Cmax with ANOVA test to evaluate the 90% confidence interval for the ratio (Test/Reference) of the population means with a logarithmic transformation prior to analysis with acceptance interval of 0.80 - 1.25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 8 hours post-administration</time_frame>
    <description>Time until Cmax is reached. Tmax is analyzed with Wilcoxon non-parametric test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>The number and type of adverse events will be reported from first drug administration (period 1) till 1 week after the second drug administration (period 2), including 6 days of washout period (total time is approximately 14 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>FABALOFEN 60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JAPROLOX TABLET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a single dose of 1 JAPROLOX速 TABLETS tablet under fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FABALOFEN 60</intervention_name>
    <description>Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose</description>
    <arm_group_label>FABALOFEN 60</arm_group_label>
    <other_name>Loxoprofen sodium 60mg/tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAPROLOX TABLET</intervention_name>
    <description>Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose</description>
    <arm_group_label>JAPROLOX TABLET</arm_group_label>
    <other_name>Loxoprofen sodium 60mg/tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males.&#xD;
&#xD;
          -  18 to 55 years old.&#xD;
&#xD;
          -  BMI in the range of 18 - 27 kg/m2, according to 1983 Metropolitan Index for adults.&#xD;
&#xD;
          -  No present or history of hypertension, diabetes, respiratory or digestive problems,&#xD;
             hepatic or renal deficiency, genetic problems nor tuberculosis (all inclusive).&#xD;
&#xD;
          -  Laboratory results (hematological, biological) within normal range; negative HIV-test&#xD;
             and HbsAg.&#xD;
&#xD;
          -  No abnormalities on ECG.&#xD;
&#xD;
          -  Willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legal incompetency.&#xD;
&#xD;
          -  Drug, alcohol or tobacco abuse.&#xD;
&#xD;
          -  Allergic history to loxoprofen or any other excipients of the study products, or&#xD;
             heparin.&#xD;
&#xD;
          -  Abnormalities in cardiovascular, digestive, immunity, hematological, endocrine,&#xD;
             neurological or psychiatric system determined by clinical physicians.&#xD;
&#xD;
          -  Suspected positive HIV-test or HbsAg by quick test or electrochemiluminescence&#xD;
             Immunoassay (ECLIA) or enzyme-linked immunosorbent assay (ELISA).&#xD;
&#xD;
          -  Any illness determined by clinical physicians within 2 weeks prior to the first&#xD;
             dosing.&#xD;
&#xD;
          -  Use of any over-the-counter drug within 1 week or prescription drug within 2 weeks&#xD;
             prior to the first dosing.&#xD;
&#xD;
          -  Donation or loss of more than 450 ml of blood within 28 days prior to the first&#xD;
             dosing.&#xD;
&#xD;
          -  History of dysphagia or digestive diseases affecting drug absorption.&#xD;
&#xD;
          -  History of difficulty in accessibility of veins in arms.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanh P Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre of Clinical Pharmacology, Hanoi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Clinical Pharmacology, Hanoi Medical University</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxoprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

